A phase 1b study of poziotinib in combination with T-DM1 in women with advanced or metastatic HER2-positive breast cancer

被引：0
|
作者：
Bhat, G.
Potter, D.
Bharadwaj, J.
Khan, N.
Shabazz, L.
Tache, J.
Yang, Z.
机构：
[1] Spectrum Pharmaceut, Irvine, CA USA
[2] Univ Minnesota, Minneapolis, MN USA
[3] Pacific Canc Med Ctr, Anaheim, CA USA
[4] Delta Hematol Oncol Associates, Portsmouth, VA USA
[5] BRCR Med Ctr, Plantation, FL USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT2-07-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-07-04
引用
收藏
页数：2
相关论文
共 50 条
  • [1] T-DM1 for HER2-positive metastatic breast cancer
    Yaqub, Farhat
    LANCET ONCOLOGY, 2013, 14 (03): : E94 - E94
  • [2] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Ian E. Krop
    Shanu Modi
    Patricia M. LoRusso
    Mark Pegram
    Ellie Guardino
    Betsy Althaus
    Dan Lu
    Alexander Strasak
    Anthony Elias
    Breast Cancer Research, 18
  • [3] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Krop, Ian E.
    Modi, Shanu
    LoRusso, Patricia M.
    Pegram, Mark
    Guardino, Ellie
    Althaus, Betsy
    Lu, Dan
    Strasak, Alexander
    Elias, Anthony
    BREAST CANCER RESEARCH, 2016, 18
  • [4] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [5] A phase 1b study of S-1 combined with trastuzumab emtansine (T-DM1) for HER2 positive metastatic breast cancer
    Kojima, Yasuyuki
    Yoshie, Reiko
    Kawamoto, Hisanori
    Shimo, Arata
    Uejima, Tomoko
    Iwatani, Tsuguo
    Motoyoshi, Ai
    Haku, Ei
    Kanemaki, Yoshihide
    Tsugawa, Koichiro
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
    Casadevall, David
    Hernandez-Prat, Anna
    Garcia-Alonso, Sara
    Arpi-Llucia, Oriol
    Menendez, Silvia
    Qin, Mengjuan
    Guardia, Cristina
    Morancho, Beatriz
    Sanchez-Martin, Francisco Javier
    Zazo, Sandra
    Gavilan, Elena
    Sabbaghi, Mohammad A.
    Eroles, Pilar
    Cejalvo, Juan Miguel
    Lluch, Ana
    Rojo, Federico
    Pandiella, Atanasio
    Rovia, Ana
    Anabell, Joan
    MOLECULAR CANCER RESEARCH, 2022, 20 (07) : 1108 - 1121
  • [7] Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer
    Jain, S.
    Nye, L.
    Santa-Maria, C.
    Bontemps, L.
    Williams, A.
    Garrett, H.
    Dammrich, E.
    Giles, F.
    Gradishar, W.
    CANCER RESEARCH, 2016, 76
  • [8] T-DM1 for residual, invasive, HER2-positive breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2019, 20 (01): : E13 - E13
  • [9] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [10] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
    Satzger, Ulla
    ONKOLOGIE, 2013, 36 (09): : 525 - 525
12345